Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00112034 · ClinicalTrials.gov registry record · Phase 4
AVONEX® Combination Trial - "ACT"
A Phase 4 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 4
- Development phase
- 350
- Enrollment target
NCT00112034 is a Phase 4 study that has completed, run by Biogen. The registered enrollment target is 350 participants.
The verdict
NCT00112034, a Phase 4 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 350 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of combination therapy with AVONEX plus low dose oral methotrexate (MTX), every other month courses of intravenous methylprednisolone (IVMP), or both in patients with continued disease activity on AVONEX monotherapy.
Interventions
- DRUG Methotrexate
- DRUG IV methylprednisolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2003-06 |
| Est. Completion | 2007-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00112034
The ClinicalTrials.gov registry entry for NCT00112034 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Methotrexate is the first listed.
NCT00112034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00112034 about?
NCT00112034 is a clinical study titled "AVONEX® Combination Trial - "ACT"". The purpose of this study is to determine the efficacy and safety of combination therapy with AVONEX plus low dose oral methotrexate (MTX), every other month courses of intravenous methylprednisolone (IVMP), or both in patients with continued disease activity on AVONEX monotherapy.
What is the current status of trial NCT00112034?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 350 participants. The study started on 2003-06. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00112034?
The interventions under investigation include: Methotrexate (DRUG), IV methylprednisolone (DRUG).
Who is sponsoring clinical trial NCT00112034?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.